EAM
NTLA icon

Eagle Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Eagle Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-269,558
Closed -$8.22M – 598
2023
Q4 		$8.22M Buy
269,558
+26,867
+11% +$772K 0.04% 303
2023
Q3 		$7.67M Buy
242,691
+7,462
+3% +$289K 0.05% 298
2023
Q2 		$9.59M Buy
235,229
+63,350
+37% +$2.57M 0.05% 269
2023
Q1 		$6.41M Sell
171,879
-15,486
-8% -$607K 0.04% 312
2022
Q4 		$6.49M Sell
187,365
-7,698
-4% -$366K 0.04% 295
2022
Q3 		$10.9M Sell
195,063
-3,969
-2% -$246K 0.07% 229
2022
Q2 		$10.3M Sell
199,032
-32,485
-14% -$1.65M 0.06% 240
2022
Q1 		$16.8M Buy
231,517
+10,113
+5% +$857K 0.09% 212
2021
Q4 		$26.8M Sell
221,404
-9,908
-4% -$1.24M 0.12% 191
2021
Q3 		$31M Sell
231,312
-34,811
-13% -$5.27M 0.14% 183
2021
Q2 		$43.1M Buy
+266,123
New +$20.7M 0.19% 167

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eagle Asset Management's NTLA Position: Q1 2024 in Review

Eagle Asset Management sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 269,558 shares — an estimated $8.22M sold.

Eagle Asset Management first reported a position in NTLA in Q2 2021 and held it in 11 quarters. The position peaked at $43.1M in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Eagle Asset Management reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Eagle Asset Management sold 269,558 Intellia Therapeutics shares in Q1 2024, an estimated $8.22M.
  • Eagle Asset Management first reported a position in Intellia Therapeutics in Q2 2021 and held it in 11 quarters.
  • Eagle Asset Management's Intellia Therapeutics position peaked at $43.1M in Q2 2021.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Eagle Asset Management's 13F filing for Q1 2024, filed 9 May 2024.